Episode 8 - Trump's FDA deregulation proposal, 21st Century Cures Act, and Value-based Reimbursement Model


Fetch error

Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on November 27, 2018 01:34 (2y ago)

What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.

Manage episode 210975243 series 2376277
By whatthepharma. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

In this episode, I open with the latest #GOBOLDY (read: Go Boldy, not GOB OLDY) campaign by the industry trade association, PhRMA, then move onto Trump's latest request to Pharma companies to lower prices, one solution of which is his proposal on lessening FDA regulations so drugs will enter into the market faster. I then move onto the 21st Century Cures Act to clear up any potential confusion on where this Act modifies FDA approvals process as well as a high-level overview of the Act. Then, I move onto what the pharma companies have proposed on lowering prices, which is through value-based reimbursement models.

11 episodes